Last edited by Vudohn
Thursday, May 14, 2020 | History

2 edition of Radiation dosimetry of radioimmunotherapy antibodies conjugated with ⁹⁰Y found in the catalog.

Radiation dosimetry of radioimmunotherapy antibodies conjugated with ⁹⁰Y

Khalid A.I. Eleissa Al-Hussan

Radiation dosimetry of radioimmunotherapy antibodies conjugated with ⁹⁰Y

by Khalid A.I. Eleissa Al-Hussan

  • 155 Want to read
  • 30 Currently reading

Published .
Written in English

    Subjects:
  • Cancer -- Radioimmunotherapy.,
  • Radiation dosimetry.,
  • Monte Carlo method.

  • Edition Notes

    Statementby Khalid A.I. Eleissa Al-Hussan.
    The Physical Object
    Pagination155 leaves, bound :
    Number of Pages155
    ID Numbers
    Open LibraryOL15494184M

      Intraperitoneal Radioimmunotherapy with a Humanized Anti-TAG (CC49) Antibody with a Deleted CH2 Region (LST). The ΔCH2 molecule and intact humanized CC49 (HuCC49) monoclonal antibody were conjugated to PA-DOTA and These studies suggest that i.p. radioimmunotherapy using radiolabeled HuCC49ΔCH2 should allow higher radiation doses Cited by: Oncology Book of , British Medical Association's Medical Book Awards Awarded first prize in the Oncology category at the BMA Medical Book Awards, Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer helps readers understand this hot pharmaceutical field with up .

    These medications were the first agents of radioimmunotherapy, and they were approved for the treatment of refractory non-Hodgkins means they are used in patients whose lymphoma is refractory to conventional chemotherapy and the monoclonal antibody rituximab.. Agents in clinical development. A set of radioimmunotherapy drugs that rely upon an alpha particle-emitting isotope ICDCM: Medical Physics, ISSN , 08/, Vol Issue 8, pp. -

      Abstract. 90 Y-ibritumomab tiuxetan is a novel radioimmunotherapeutic agent recently approved for the treatment of relapsed or refractory low-grade, follicular, or CD20+ transformed non-Hodgkin’s lymphoma (NHL). 90 Y-ibritumomab tiuxetan consists of a murine monoclonal antibody covalently attached to a metal chelator, which stably chelates In for imaging and 90 Y for by: Because breast cancer cells often express either Her2/neu or carcinoembryonic antigen (CEA) or both, these tumor markers are good targets for radioimmunotherapy using Ylabeled antibodies. We performed studies on nude mice bearing xenografts from MCF7, a cell line that has low Her2 and CEA expression, to more accurately reflect the more usual situation in breast by:


Share this book
You might also like
Masonic year book.

Masonic year book.

The fox and the goose, or, The widows husband

The fox and the goose, or, The widows husband

young Louisa M. Alcott

young Louisa M. Alcott

Fangs of the werewolf

Fangs of the werewolf

Tax-Sheltered Annuity Programs for Employees of Public Schools and Certain Tax-Exempt Organizations, Publication 571, 1995.

Tax-Sheltered Annuity Programs for Employees of Public Schools and Certain Tax-Exempt Organizations, Publication 571, 1995.

Tidemarks

Tidemarks

Historic textiles reproduced for today.

Historic textiles reproduced for today.

outline of the building of culture

outline of the building of culture

The cowboy catalog

The cowboy catalog

The Oxford History of Britain: Volume 5

The Oxford History of Britain: Volume 5

Forms of Justice

Forms of Justice

Soil Survey.

Soil Survey.

Radiation dosimetry of radioimmunotherapy antibodies conjugated with ⁹⁰Y by Khalid A.I. Eleissa Al-Hussan Download PDF EPUB FB2

Graduate Thesis Or Dissertation Radiation dosimetry of radioimmunotherapy antibodies conjugated with ⁹⁰Y Public Deposited. Analytics × Add to Author: Khalid A.I. Eleissa Al-Hussan.

Download PDF: Sorry, we are unable to provide the full text but you may find it at the following location(s): (external link). Thus, as the red marrow is the target organ, in radioimmunotherapy with anti-CD45 antibody, preloading with unlabeled antibody is a method to increase the absorbed dose to the target cells.

Radioimmunotherapy (RIT) represents a selective internal radiation therapy, that is, the use of radionuclides conjugated to tumor-directed monoclonal antibodies (including those fragments) or peptides.

In a clinical field, two successful examples of this treatment protocol are currently extended by 90Y-ibritumomab tiuxetan (Zevalin) and I-tositumomab (Bexxar), both of which are anti-CD20 monoclonal antibodies coupled to cytotoxic radioisotopes Cited by: Zevalin consists of a murine anti‐CD20 monoclonal antibody (ibritumomab) conjugated to the linker‐chelator tiuxetan, which securely chelates indium‐ ( In) for imaging and dosimetry and yttrium‐90 (90 Y) for radioimmunotherapy (RIT).

Previous trials involving rituximab‐naïve patients have demonstrated excellent targeting of Cited by: The purpose of the present study was to estimate radiation dosimetry for both antibodies (mAbs) using positron emission tomography (PET) imaging, and evaluate the effect of internalization on.

Melanoma is a cancer with increasing incidence and there is a need for alternatives to immunotherapy within effective approaches to treatment of metastatic melanoma. We performed comparative radioimmunotherapy (RIT) of experimental BF10 melanoma with novel humanized IgG to melanin h8C3 labeled with a beta emitter, Lu, and an alpha-emitter, Bi, as well as biodistribution, Cited by: 2.

Radioimmunotherapy (RIT) represents a selective internal radiation therapy, that is, the use of radionuclides conjugated to tumor-directed monoclonal antibodies (including those fragments) or peptides.

In a clinical field, two successful examples of this treatment protocol are currently extended by 90 Y-ibritumomab tiuxetan (Zevalin) and I-tositumomab (Bexxar), both of which are anti-CD20 monoclonal antibodies coupled to cytotoxic radioisotopes Cited by: Radioimmunotherapy represents an attempt to augment the single-agent efficacy of this therapeutic approach in NHL by conjugating therapeutic radionuclides to the monoclonal antibodies in order to deliver radiation to these tumors [], which are known to be more radiosensitive than solid tumors and other types of cancer [6,7,8,9].The mechanism of action of radioimmunotherapy on tumor cells Author: Christos Sachpekidis, David B.

Jackson, Theodoros G. Soldatos. Radioimmunotherapy utilizes radionuclides conjugated to monoclonal antibodies to target and destroy tumor cells, by combining radiolytic and biologic mechanisms of action.

The penetrating effect of radiation allows treatment of poorly vascularized or bulky tumors, since malignant cells inaccessible to a targeting antibody can be killed at a distance by the ionizing radiation.

Elgqvist J. Astatine radioimmunotherapy of ovarian cancer – Therapeutic efficay, myelotoxocity and radiation dosimetry in an animal model.

Book published at Lambert Academic Publishing in ISBN: Radionuclides conjugated to antibodies are known as radioimmunotherapy (RIT).

Cancer RIT is a subspecialty of radiation oncology and nuclear medicine. Radioisotopes are chosen based on half‐life, energy path length, and ability to conjugate radioisotope to the tumor target without altering the target. Radioimmunotherapy of metastatic colorectal tumours with iodinelabelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab′)2 by: Kaminski MS, Fig LM, Zasadny KR et al.

() Imaging, dosimetry, and radioimmunotherapy with iodinelabeled anti-CD37 (MB-1) antibody in B-cell lymphoma.

J Cited by: 6. Radioimmunotherapy, also known as systemic targeted radiation therapy, uses antibodies, antibody fragments, or compounds as carriers to guide radiation to the targets.

It is a topic rapidly increasing in importance and success in treatment of cancer patients. This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and 5/5(8).

Radiation effects on biological tissues are caused by the energy emitted by radioactive decay that is deposited in tissues. For radioimmunotherapy (RIT) we are most concerned with radioisotopes, which decay with particulate and non-penetrating radiations such as alpha particles, beta particles, auger, or low-energy by:   The aim of this study was to compare the therapeutic efficacy of two different activity levels of the Bi-labeled monoclonal antibody MX35 in an ovarian cancer model.

Sixty female BALB/c (nu/nu) mice were inoculated intraperitoneally with human ovarian cancer cells (OVCAR-3). Two weeks later, 40 mice were injected intraperitoneal (i.p.) with 1 ml of Bi-MX35, 3 MBq/mL (n = 20), or 9 Cited by: 2.

Free Online Library: Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.(Report) by "The Scientific World Journal"; Biological sciences Environmental issues Antibodies Health aspects Cancer Care and treatment Methods Cancer treatment Radioisotopes Viral antibodies.

When delivered at a sufficient dose and dose rate to a neoplastic mass, radiation can kill tumor cells. Because cancer frequently presents as a disseminated disease, it is imperative to deliver cytotoxic radiation not only to the primary tumor but also to distant metastases, while reducing exposure of healthy organs as much as possible.

Monoclonal antibodies and their fragments, labeled with Cited by: It is necessary to determine the quantity of radiolabeled antibody to administer to maximize the radiation dose to the tumor while not exceeding tolerance levels of critical normal tissues, In contrast to external beam radiation therapy dosimetry, the tumor dosimetry for radiolabeled antibody therapy is dependent on a number of variables including: (1) kinetics of biodistribution, tumor uptake and retention of the radiolabeled antibody.

Ionizing radiation – hazard symbol. Radiation dosimetry is the measurement, calculation and assessment of the absorbed doses and assigning those doses to individuals. It is the science and practice that attempts to quantitatively relate specific measures made in a radiation field to chemical and/or biological changes that the radiation would produce in a target.Monoclonal antibodies (mAbs) offer new therapeutic choices for patients with hematologic malignancies.

1,2 Although the single-agent activity of most mAbs has generally been modest and short lived, the different mechanisms of action and nonoverlapping toxicity of mAbs has enabled them to be combined with chemotherapy and radiotherapy to greatly improve response rates. 3 Radioimmunotherapy (RIT Cited by: Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, Hanson CA, Normolle DP, Mudgett E, Liu CP, et al.

() Imaging, dosimetry, and radioimmunotherapy with iodine labeled anti-CD37 antibody in B-cell lymphoma.